Anti-Human IL-4 (STAT6) (Clone CPTC-STAT6-1) – Purified No Carrier Protein

STAT6 synthetic peptide GYVPATIK

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

EB0969D-3F6-H1/K1 activity is directed against the human STAT6 peptide sequence GYVPATIK.

CPTC-STAT6-1

Signal transducer and activator of transcription (STAT) proteins comprise a family of transcription factors involved in various JAK/STAT signaling pathways responsible for immune fitness, inflammation, hematopoiesis, tissue repair, apoptosis, and adipogenesis¹. When STATs are tyrosine-phosphorylated by JAKs, they dimerize and are transported into the nucleus to enact gene regulation, where different STATs have different, nonredundant functions. The STAT family has seven members, STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6, with some members expressing different splice isoforms by cell or tissue type.

STAT6 mainly functions in transduction of IL-4 and IL-13 signals, playing roles in innate immunity, promoting the proliferation and maturation of B cells, mediating MHC-II and IgE expression, activating mast cells, inducing homing-related genes in immune cells¹, and inhibiting cholesterol synthesis². Activation of STAT6 induces Th2 cell differentiation, immunoglobulin isotype conversion, and in T cells inhibits VAL-4 expression, which inhibits infiltration of CD8+ T cells into tumors¹. Additionally, STAT6 activation induces CCL2 expression and recruits T cells, macrophages, and monocytes. Uniquely to STAT6 from amongst the STATs, STAT6 can be activated by viruses without JAK involvement. Dysregulation of JAK/STAT signaling promotes tumorigenesis and autoimmune diseases, and therefore JAK/STAT signaling is a therapeutic target.

EB0969D-3F6-H1/K1 was generated for use in immuno-MRM assays in rabbit using a synthetic peptide derived from human STAT6, GYVPATIK³. EB0969D-3F6-H1/K1 does not detect STAT6 by bio-layer interferometry, surface plasmon resonance, immunohistochemistry, or immunofluorescence⁴. EB0969D-3F6-H1/K1 does detect STAT6 by indirect ELISA.

STAT6 localizes to the cytoplasm and nucleus.

NCOA1

1 Hu X, Li J, Fu M, et al. Signal Transduct Target Ther. 6(1):402. 2021.
2 Li YJ, Zhang C, Martincuks A, et al. Nat Rev Cancer. 23(3):115-134. 2023.
3 Whiteaker JR, Lundeen RA, Zhao L, et al. Front Immunol. 12:765898. 2021.
4 https://antibodies.cancer.gov/detail/CPTC-STAT6+Peptide+1